Gaucher's Market Research Reports & Industry Analysis
Gaucher's Industry Research & Market Reports
-
Gaucher Disease - Opportunity Assessment and Forecast
... regimen for Type 1 GD and Type 3 GD is dominated by ERTs and SRTs (Cerezyme, VPRIV, Elelyso, Cerdelga, Zavesca). There are several unmet needs in the GD landscape, including the lack of effective therapies ... Read More
-
Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Others) By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, Others), By Region, And Segment Forecasts, 2023 - 2030
... 2030 Gaucher Disease Drugs Market Growth & Trends The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according ... Read More
-
Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
... Points, Status, Sponsor Type and Top Countries, 2023 Update provides an overview of Gaucher Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Gaucher Disease. Report includes an ... Read More
-
Glycomic Therapeutics Global Market Report 2023 Including: 1) By Class: Isolated; Synthetic 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher’s Disease; Mps-1 And IV; Cancer; Alzheimer’s Disease; Influenza Type A And B Covering: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
... Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons4) ... Read More
-
Enzyme Replacement Therapy Market Size - By Enzyme (Alglucosidase alfa, Agalsidase beta, Imiglucerase), Indication (Gaucher, MPS, Pompe, SCID, Fabry), Route of Administration, End-user, Global Forecast 2023-2032
... over 7% CAGR from 2023 to 2032, driven by the broader acceptance of biologics and standard treatments for various genetic disorders. Biologics, including enzyme replacement therapy (ERT) are gaining prominence as advanced and targeted treatments ... Read More
-
Gaucher Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
... markets. The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 2.1% from 2024 to 2030. The major drivers for this market are the increasing prevalence ... Read More
-
Global Pompe Disease Therapeutics Market - 2023-2030
... The global Pompe disease therapeutics market is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030). Pompe disease is an inherited lysosomal condition induced by a lack of the enzyme acid alpha-glucosidase ... Read More
-
Global Gaucher’s Disease Treatment Market Growth 2023-2029
... at a CAGR of 3.7% from 2023 to 2029. United States market for Gaucher’s Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
-
2023 Global: Gaucher And Pompe Diseases Enzyme Replacement Therapy (Ert) Market - Innovative Markets Forecast (2029) report
... analyzies the market size, projected growth/decline and regional data for the period 2018 through 2029. Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product ... Read More
-
Global Gaucher's Disease Treatment Market Report and Forecast 2023-2031
... at a CAGR of 3.6% during the forecast period of 2023-2031 to reach a value of USD 2.1 billion by 2031. The market growth can be attributed to the increasing prevalence of Gaucher's disease and ... Read More
-
2023 Global Forecast for Gaucher And Pompe Diseases Enzyme Replacement Therapy (Ert) Market (2024-2029 Outlook)-High Tech & Emerging Markets Report
... the market for over 50 countries. The product or service category is within the NAICS Medical Laboratories industry. The product or service category is within the NAICS Medical Laboratories industry. The global market is expected ... Read More
-
Plant-Based Biologics Market By Product Type (Leaf-based, Seed-Based, Fruit-based, Others), By Source (Carrot, Tobacco, Rice, Duckweed, Others), By Target Disease (Gaucher Disease, Fabry Disease, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
... biologics market is envisioned to garner $182.9 million by 2031, growing from $116.1 million in 2021 at a CAGR of 4.8% from 2022 to 2031. The current production platforms, which are mostly based on mammalian ... Read More
-
Gaucher Disease Pipeline Report, 2023- Planned Drugs by Phase, Mechanism of Action, Route of Administration, Type of Molecule, Market Trends, Developments, and Companies
... clinical stage pipeline candidates under development as of H1- 2023. For each of the Gaucher Disease pipeline candidate, details of leading companies, phase of development, mechanism of action, route of administration, molecule type, and other ... Read More
-
Gaucher’s Disease - Drug Pipeline Landscape, 2023
... including the spleen and liver. The condition is mainly of 3 types: Gaucher disease type 1, Gaucher disease type 2, and Gaucher disease type 3. Gaucher Disease's main cause is mutations in the GBA1 gene, ... Read More
-
Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029
... End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029 Global Enzyme Replacement Therapy Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth ... Read More
-
Virus-Like Particles (VLP’s) Market Analysis And Forecast To 2032: By Product Type (Hepatitis, Cancer/HPV, Gaucher Disease), Source (Yeast, Insect Cell, Plant, Others), Application (Vaccine, Therapeutics), And Region
... period. Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. Market Trends and Drivers Consistent R&D ... Read More
-
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape. Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung ... Read More
-
North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and ... Read More
-
Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and ... Read More
-
Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
Europe Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins ... Read More
-
Global Enzyme Replacement Therapy Market - 2022-2029
... of 5.1 % during the forecast period (2022-2029). Enzyme Replacement Therapy (ERT) is the treatment involved for rare diseases. According to Global genes.org, around 80.0% of rare diseases are categorized under genetic origin. There are ... Read More
-
Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]
... Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins ... Read More
-
Lysosomal Disease Treatment Market By Disease Type (Gaucher's Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others), By End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
... Global Opportunity Analysis and Industry Forecast, 2021-2031 The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from ... Read More
Research Assistance
